Latest Headlines
Age should not affect chemotherapy choice for stage IV lung cancer: guidelines
Early PET-CT predicts treatment response of head and neck cancer
Evidence scarce to support RF ablation of colorectal CA metastases in the liver
Casopitant helps curb chemotherapy emesis
Australian scientists plan to regrow breasts after cancer
NEWS PROVIDED BY 
VIEW ALL NEWSStudy sheds light on deadly childhood cancer
LONDON (Reuters) - A gene involved in cell division also helps fuel a deadly childhood cancer called neuroblastoma and could offer a new way to develop drugs to treat the disease, German researchers said on Monday.
The study published in the journal Cancer Cell found that a protein produced by the AURKA gene feeds a different gene called MYCN, which scientists know plays a key role in fuelling tumour growth in children with neuroblastoma, the researchers said.
"The MYCN gene is one that no pharmaceutical company have been able to target," Martin Eilers, a researcher at Wurzburg University in Germany, who led the study, said in a telephone interview.
"Our finding offers hope we can make new (drugs) to attack this cancer."
Neuroblastoma accounts for 15 percent of childhood cancer deaths, with just a 40 percent survival rate, even though it only causes about seven percent of all paediatric cancers.
In August, U.S. researchers said they had found a variation in a gene called ALK that causes most inherited forms of the disease by helping cells proliferate. Out-of-control proliferation is the hallmark of cancer.
Eilers and his team screened 200 genes dependent on MYCN in children with neuroblastoma and found that the protein produced by AURKA was key to the wild cell growth.
Current drugs that inhibit cell growth will not work but AURKA is a promising target for new treatments because there are already substances in the body that attack the protein. That means, in theory, newly developed drugs could do the same.
"This is potentially a way you can get at and interrupt these tumours," Eilers said in a telephone interview.
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 